Biomea Fusion Completes Enrollment in Type 2 Diabetes Trial

Shares in Biomea Fusion (Nasdaq: BMEA) climbed this week after the company announced it has completed the enrollment of 260 type 2 diabetes in the first three dose expansion arms of its COVALENT-111 study. Biomea is evaluating BMF-219, an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells, directly addressing the root cause of diabetes by proliferating the failing pool of these cells.

Commenting on the news, Juan Pablo Frias, MD, Biomea Fusion’s Chief Medical Officer, “We are thrilled to announce the important milestone of completing enrollment of the first three expansion arms of COVALENT-111. In the dose escalation arms, after only 4 weeks of BMF-219 dosing, many participants demonstrated durable glycemic control at Week 26. To date, we have not seen an agent with such a profound impact on type 2 diabetes while off therapy.”

COVALENT-111 is a multi-site, randomized, double-blind, placebo-controlled Phase 1/2 study. The Phase 1 portion has been completed, and the Phase 2 portion will evaluate ascending dose cohorts and includes adult patients with type 2 diabetes uncontrolled by standard of care medicines.

According to the CDC, about 90–95% of the more than 38 million Americans with diabetes have type 2 diabetes.

About Biomea Fusion
Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response. We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure. Visit us at and follow us on LinkedIn, Twitter and Facebook.


Share This Article


About the Author

Biomea Fusion Completes Enrollment in Type 2 Diabetes Trial

Catie Corcoran

Biotech Editor